Prognosis is still poor in patients with posttransplant C3 glomerulopathy despite eculizumab use
Clin Kidney J
.
2024 Jun 20;17(7):sfae190.
doi: 10.1093/ckj/sfae190.
eCollection 2024 Jul.
Authors
Safak Mirioglu
1
2
,
Rabia Hacer Hocaoglu
1
,
Arzu Velioglu
3
,
Yasemin Ozluk
4
,
Ahmet Burak Dirim
1
,
Aysegul Oruc
5
,
Ozgur Akin Oto
1
,
Halil Yazici
1
,
Yasar Caliskan
1
6
Affiliations
1
Division of Nephrology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
2
Department of Immunology, Istanbul University Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.
3
Division of Nephrology, Marmara University School of Medicine, Istanbul, Turkey.
4
Department of Pathology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
5
Division of Nephrology, Bursa Uludag University Faculty of Medicine, Bursa, Turkey.
6
Center for Abdominal Transplantation, Saint Louis University School of Medicine, St Louis, MO, USA.
PMID:
39021814
PMCID:
PMC11252667
DOI:
10.1093/ckj/sfae190
No abstract available